News Archive

MIMETAS, leader in organ-on-a-chip products and tissue models, has secured 20.5 million USD in financing from an international syndicate from Asia and Europe. Mimetas will use the proceeds of this Series B financing round to expand its global commercial footprint with the OrganoPlate® organ-on-a-chip platform. In addition, the company will broaden its product portfolio, establish tissue production facilities, develop novel OrganoPlate® products and expand into clinical market segments, including personalized medicine. The company has operations in the Netherlands, USA and Japan.

The D.C. area saw its biggest first quarter in startup funding in at least 16 years, with companies raking in more than $473.3 million in venture capital with the biotech and software sectors leading the way, according to data provided by PitchBook.

In 2016, a mother filed a lawsuit relating to the death of her son Christian against a diagnostic company. When Christian began experiencing a series of unrelenting seizures, the company performed a massive battery of tests, including the sequencing of a gene called SCN1A. At the time, the company reported that he had a variant of unknown significance (VUS) there. What the company did not realize was that there was a peer-reviewed study that had identified the same SCN1A mutation in an Australian family one year earlier. Christian received inappropriate treatment and died from a seizure months later.

What’s Working in Washington EXTRA is an opportunity for us to discuss an issue of particular interest to the region. We’re talking today about life science, biotechnology, medical devices, and how these industries are successful and well-represented represented here in the D.C. region. Joining us to discuss the growth of these sectors are two experts: Richard Bendis, president & CEO of BioHealth Innovation Incorporated, and Jeff Gallagher, CEO of Virginia Biotechnology Association, or VABio.

TEDCO CEO George Davis has spent several months in his new role traveling the state and talking to startups and other tech industry players, trying to figure out how his organization can best serve Maryland’s entrepreneurial community beyond what it has been doing for the past 20 years.

May 15 & 16, 2018 – Hyatt Regency San Francisco Airport

The Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research Small Business and Industry Assistance (CDER SBIA), and Center for Devices and Radiological Health (CDRH) Division of Industry and Consumer Education (DICE) are pleased to announce a co-sponsored event developed just for you.

Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leader in the field of antibody-drug conjugates (ADCs), today announced the appointment of Robert Iannone, M.D., M.S.C.E., as Head of Research & Development and Chief Medical Officer, effective today. In his new role, Dr. Iannone will oversee and lead all clinical development, regulatory, pre-clinical, translational research and medical affairs strategies and activities of the Company. Dr. Iannone brings more than thirteen years of experience in clinical drug development, including the approval of several targeted and immuno-oncology medicines at AstraZeneca/MedImmune and Merck & Co.

The 2018 Maryland Incubator Company of the Year Awards publicly recognizes achievements by current clients and graduates of Maryland incubators and provides a forum for the nominees to increase their visibility in the business, technology and investment communities.

Business incubators support new and early-stage businesses in Maryland. In 1986, the first public incubator was established at the University of Maryland in College Park. Recognizing the economic challenges facing new companies, business incubators are facilities that provide reasonable market rents, shared services and technical assistance to start-ups and early-stage companies, including manufacturing, biotech, service and technology firms.

An aerospace company born out of the University of Maryland, College Park has raised $1.45 million in a round led by the University System of Maryland and the Abell Foundation.

Funding has been flowing into biotech over the past few years.

Over one week earlier this year, biotech and healthcare startups raised almost $1 billion in capital. And on Tuesday, a cancer-drug startup called Allogene raised $300 million in its series A round.